Abbott Laboratories $ABT Shares Bought by Voya Investment Management LLC

Voya Investment Management LLC boosted its position in Abbott Laboratories (NYSE:ABT – Free Report) by 665.2% in the 3rd quarter, Holdings Channel reports. The firm owned 3,224,177 shares of the healthcare product maker’s stock after buying an additional 2,802,830 shares during the quarter. Voya Investment Management LLC’s holdings in Abbott Laboratories were worth $318,646,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of ABT. Bank of America Corp DE bought a new position in shares of Abbott Laboratories during the second quarter valued at approximately $1,603,607,000. Legal & General Group Plc bought a new stake in shares of Abbott Laboratories during the 2nd quarter worth approximately $1,082,524,000. Flossbach Von Storch SE bought a new stake in shares of Abbott Laboratories during the 2nd quarter worth approximately $902,938,000. Jupiter Topco LLC bought a new stake in shares of Abbott Laboratories during the 2nd quarter worth approximately $732,788,000. Finally, BlackRock Inc. boosted its holdings in Abbott Laboratories by 4.6% during the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock valued at $13,843,610,000 after acquiring an additional 6,769,518 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Activity

In other news, EVP Mary Moreland sold 3,500 shares of the stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $116.00, for a total transaction of $406,000.00. Following the transaction, the executive vice president owned 100,791 shares of the company’s stock, valued at approximately $11,691,756. This represents a 3.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.46% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on ABT shares. Weiss Ratings raised Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, September 18th. Barclays began coverage on Abbott Laboratories in a research report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 target price for the company. Wells Fargo & Company boosted their target price on shares of Abbott Laboratories from $112.00 to $119.00 and gave the company an “overweight” rating in a research note on Thursday, October 22nd. Royal Bank Of Canada cut their price target on shares of Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating on the stock in a report on Thursday, October 22nd. Finally, Wolfe Research raised shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target on the stock in a research note on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $118.32.

Read Our Latest Analysis on ABT

Abbott Laboratories Stock Down 2.6%

Shares of NYSE ABT opened at $104.64 on Wednesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.00 and a current ratio of 1.45. The firm has a market capitalization of $181.23 billion, a price-to-earnings ratio of 39.04, a PEG ratio of 1.88 and a beta of 0.54. The stock has a 50 day moving average price of $103.89 and a 200 day moving average price of $101.74. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $132.02.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.42. The company had revenue of $13.01 billion for the quarter, compared to analysts’ expectations of $12.99 billion. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. Abbott Laboratories’s revenue was up 14.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.30 earnings per share. Sell-side analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, November 16th. Shareholders of record on Thursday, October 15th were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. The ex-dividend date was Thursday, October 15th. Abbott Laboratories’s dividend payout ratio is currently 94.03%.

About Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Featured Stories

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.